- Home
- E vs ALNY Comparison
E vs ALNY Comparison
Compare E & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- E
- ALNY
- Stock Information
- Founded
- E 1953
- ALNY 2002
- Country
- E Italy
- ALNY United States
- Employees
- E N/A
- ALNY N/A
- Industry
- E Oil & Gas Production
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- E Energy
- ALNY Health Care
- Exchange
- E Nasdaq
- ALNY Nasdaq
- Market Cap
- E 52.3B
- ALNY 60.7B
- IPO Year
- E 1995
- ALNY 2004
- Fundamental
- Price
- E $38.08
- ALNY $459.45
- Analyst Decision
- E Hold
- ALNY Strong Buy
- Analyst Count
- E 2
- ALNY 27
- Target Price
- E $31.60
- ALNY $483.89
- AVG Volume (30 Days)
- E 274.0K
- ALNY 1.1M
- Earning Date
- E 10-24-2025
- ALNY 10-30-2025
- Dividend Yield
- E 4.03%
- ALNY N/A
- EPS Growth
- E 7.76
- ALNY N/A
- EPS
- E 0.96
- ALNY 0.33
- Revenue
- E $101,555,790,226.00
- ALNY $3,210,070,000.00
- Revenue This Year
- E N/A
- ALNY $65.55
- Revenue Next Year
- E N/A
- ALNY $41.48
- P/E Ratio
- E $18.95
- ALNY $1,396.19
- Revenue Growth
- E N/A
- ALNY 53.24
- 52 Week Low
- E $24.65
- ALNY $205.87
- 52 Week High
- E $38.47
- ALNY $495.55
- Technical
- Relative Strength Index (RSI)
- E 69.07
- ALNY 54.22
- Support Level
- E $36.16
- ALNY $417.00
- Resistance Level
- E $38.33
- ALNY $459.27
- Average True Range (ATR)
- E 0.43
- ALNY 16.36
- MACD
- E 0.11
- ALNY 0.71
- Stochastic Oscillator
- E 85.29
- ALNY 67.55
About E ENI S.p.A.
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2024, the company produced 0.8 million barrels of liquids and 4.8 billion cubic feet of natural gas per day. At end-2024, Eni held reserves of 6.5 billion barrels of oil equivalent, 46% of which are liquids. The Italian government owns a 30.5% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity called Plenitude, which it will likely list publicly at some point.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.